- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Lupin Limited — Updates, 03-09-2025: Press Release
03-09-2025 | 01:03 pm
03-09-2025 | 01:03 pm
Lupin's Nanomi platform achieved US FDA approval for Risperidone long-acting injectable, securing 180-day exclusivity. This validates their complex injectables strategy. The reference drug's US annual sales were USD 19 Cr, signaling significant market opportunity.
No comments yet. Be the first to comment!